Found: 6
Select item for more details and to access through your institution.
Development of the "Hamburg Best Practice Guidelines for ICV−Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
- Published in:
- Journal of Child Neurology, 2021, v. 36, n. 8, p. 635, doi. 10.1177/0883073821989154
- By:
- Publication type:
- Article
Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.
- Published in:
- Journal of Child Neurology, 2021, v. 36, n. 6, p. 468, doi. 10.1177/0883073820977997
- By:
- Publication type:
- Article
Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Congenital myasthenic syndromes: Achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: A study of 680 patients.
- Published in:
- Human Mutation, 2012, v. 33, n. 10, p. 1474, doi. 10.1002/humu.22130
- By:
- Publication type:
- Article
Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes—A Retrospective Single Centre Cohort Study.
- Published in:
- Frontiers in Human Neuroscience, 2020, v. 14, p. N.PAG, doi. 10.3389/fnhum.2020.560860
- By:
- Publication type:
- Article
Visual perception and macular integrity in non-classical CLN2 disease.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 11, p. 3693, doi. 10.1007/s00417-022-05662-1
- By:
- Publication type:
- Article